^
    Back
    Association details:
    Biomarker:KRAS G12D
    Cancer:Pancreatic Ductal Adenocarcinoma
    Drug:MRTX1133 (KRAS G12D inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Cancer Discov
    Title:

    Efficacy of a small molecule inhibitor of KrasG12D in immunocompetent models of pancreatic cancer

    Published date:
    12/06/2022
    Excerpt:
    In vivo, MRTX1133 prompted deep tumor regressions in all models tested, including complete or near-complete remissions after 14d….These results validate the specificity, potency, and efficacy of MRTX1133 in immunocompetent KRASG12D-mutant PDAC models…
    DOI:
    https://doi.org/10.1158/2159-8290.CD-22-1066